BioDiscovery, Illumina Collaborate
News May 11, 2016
BioDiscovery, Inc. has announced a collaborative agreement with Illumina Inc. to provide BioDiscovery’s NxClinical software as the secondary data analysis and management tool for Illumina’s CytoSeq™ assay. The NxClinical software will be offered with the CytoSeq product to provide an easy-to-use interactive tool for visualization and interpretation of genomic events.
Illumina’s NGS based CytoSeq assay will extend beyond traditional microarray-based cytogenetics assays for detection of copy number variation (CNV) and absence of heterozygosity (AOH), but also adds the ability to identify single nucleotide variation (SNV), all in a single assay. Coupled with BioDiscovery’s NxClinical software for analysis and interpretation of genomic events, the new solution will provide customers with a powerful and cost effective research tool for studying CNVs, AOH, and mutations in genetic disorders.
“We are extremely pleased to be working with Illumina to provide an analytical and data management software for CytoSeq,” said Dr. Soheil Shams, President of BioDiscovery. “Our expertise in integrated genomic data analysis and visualization software perfectly complements Illumina’s robust and advanced technologies for sequencing and microarrays. NxClinical was designed to provide reliability and consistency in the analysis and reporting of genomic events and encompasses many automated features that increase efficiency and eliminate repetitive tasks. The software’s ability to handle different types of data such as CNV, allelic events, and sequence variants makes it an ideal tool for CytoSeq.”
“We are proud to partner with BioDiscovery and are excited to offer NxClinical software with this product. We feel this collaboration offers the market a transformational research tool for cytogenetic and molecular genetic applications,” said Rich Shippy, Senior Director of Product Marketing at Illumina.
The two companies are working together to ensure customers will have a comprehensive solution for analysis, visualization, and interpretation of genomic events. The NxClinical software will directly read CytoSeq results to process sample data and provide results in an easy-to-use, powerful, and interactive interface.
An artificial intelligence (AI) approach based on deep learning convolutional neural network (CNN) could identify nuanced mammographic imaging features specific for recalled but benign (false-positive) mammograms and distinguish such mammograms from those identified as malignant or negative.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019